0 XP   0   0   0

Evelo Biosciences Inc










Financial Health of Evelo Biosciences Inc




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Evelo Biosciences Inc
Buy, Hold or Sell?

Should you buy, hold or sell Evelo Biosciences Inc?

I guess you are interested in Evelo Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Evelo Biosciences Inc

Let's start. I'm going to help you getting a better view of Evelo Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Evelo Biosciences Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Evelo Biosciences Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Evelo Biosciences Inc. The closing price on 2022-12-02 was $2.16 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Evelo Biosciences Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

1.1. Profitability of Evelo Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Evelo Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Evelo Biosciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Evelo Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.6%+223.6%
TTM--281.7%+281.7%
YOY--344.8%+344.8%
5Y--450.1%+450.1%
10Y--541.0%+541.0%
1.1.2. Return on Assets

Shows how efficient Evelo Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Evelo Biosciences Inc to the Biotechnology industry mean.
  • -27.3% Return on Assets means that Evelo Biosciences Inc generated $-0.27 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Evelo Biosciences Inc:

  • The MRQ is -27.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -34.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.3%TTM-34.9%+7.6%
TTM-34.9%YOY-23.1%-11.9%
TTM-34.9%5Y-22.5%-12.4%
5Y-22.5%10Y-25.5%+2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.3%-9.9%-17.4%
TTM-34.9%-8.9%-26.0%
YOY-23.1%-9.3%-13.8%
5Y-22.5%-11.7%-10.8%
10Y-25.5%-12.7%-12.8%
1.1.3. Return on Equity

Shows how efficient Evelo Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Evelo Biosciences Inc to the Biotechnology industry mean.
  • -85.7% Return on Equity means Evelo Biosciences Inc generated $-0.86 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Evelo Biosciences Inc:

  • The MRQ is -85.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -129.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-85.7%TTM-129.6%+43.8%
TTM-129.6%YOY-54.9%-74.6%
TTM-129.6%5Y-57.3%-72.3%
5Y-57.3%10Y-65.3%+8.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-85.7%-12.0%-73.7%
TTM-129.6%-11.5%-118.1%
YOY-54.9%-10.8%-44.1%
5Y-57.3%-14.2%-43.1%
10Y-65.3%-15.2%-50.1%

1.2. Operating Efficiency of Evelo Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Evelo Biosciences Inc is operating .

  • Measures how much profit Evelo Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Evelo Biosciences Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Evelo Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--271.0%+271.0%
YOY--325.9%+325.9%
5Y--454.0%+454.0%
10Y--537.1%+537.1%
1.2.2. Operating Ratio

Measures how efficient Evelo Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Evelo Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM-3.504-3.504
YOY-3.604-3.604
5Y-5.132-5.132
10Y-6.371-6.371

1.3. Liquidity of Evelo Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Evelo Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.52 means the company has $4.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Evelo Biosciences Inc:

  • The MRQ is 4.525. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.002. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.525TTM4.002+0.523
TTM4.002YOY5.843-1.841
TTM4.0025Y9.349-5.348
5Y9.34910Y8.434+0.915
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5255.117-0.592
TTM4.0025.755-1.753
YOY5.8435.854-0.011
5Y9.3496.511+2.838
10Y8.4346.222+2.212
1.3.2. Quick Ratio

Measures if Evelo Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Evelo Biosciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.29 means the company can pay off $4.29 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Evelo Biosciences Inc:

  • The MRQ is 4.291. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.828. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.291TTM3.828+0.463
TTM3.828YOY5.695-1.867
TTM3.8285Y9.994-6.166
5Y9.99410Y8.690+1.304
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2914.284+0.007
TTM3.8284.664-0.836
YOY5.6954.787+0.908
5Y9.9945.218+4.776
10Y8.6905.182+3.508

1.4. Solvency of Evelo Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Evelo Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Evelo Biosciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.68 means that Evelo Biosciences Inc assets are financed with 68.1% credit (debt) and the remaining percentage (100% - 68.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Evelo Biosciences Inc:

  • The MRQ is 0.681. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.896. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.681TTM0.896-0.215
TTM0.896YOY0.545+0.351
TTM0.8965Y0.464+0.432
5Y0.46410Y0.495-0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6810.278+0.403
TTM0.8960.277+0.619
YOY0.5450.306+0.239
5Y0.4640.367+0.097
10Y0.4950.403+0.092
1.4.2. Debt to Equity Ratio

Measures if Evelo Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Evelo Biosciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 213.9% means that company has $2.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Evelo Biosciences Inc:

  • The MRQ is 2.139. The company is just not able to pay all its debts with equity.
  • The TTM is 3.450. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.139TTM3.450-1.311
TTM3.450YOY1.283+2.167
TTM3.4505Y1.278+2.171
5Y1.27810Y1.317-0.039
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1390.315+1.824
TTM3.4500.317+3.133
YOY1.2830.319+0.964
5Y1.2780.403+0.875
10Y1.3170.462+0.855

2. Market Valuation of Evelo Biosciences Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Evelo Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Evelo Biosciences Inc to the Biotechnology industry mean.
  • A PE ratio of -7.46 means the investor is paying $-7.46 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Evelo Biosciences Inc:

  • The EOD is -7.633. Company is losing money. -2
  • The MRQ is -7.456. Company is losing money. -2
  • The TTM is -16.284. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-7.633MRQ-7.456-0.177
MRQ-7.456TTM-16.284+8.828
TTM-16.284YOY-40.022+23.738
TTM-16.2845Y-32.878+16.594
5Y-32.87810Y-28.590-4.288
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.633-8.986+1.353
MRQ-7.456-9.792+2.336
TTM-16.284-16.243-0.041
YOY-40.022-20.876-19.146
5Y-32.878-16.665-16.213
10Y-28.590-14.732-13.858
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Evelo Biosciences Inc.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Evelo Biosciences Inc:

  • The MRQ is 325.525. Seems overpriced? -1
  • The TTM is 213.962. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ325.525TTM213.962+111.563
TTM213.962YOY335.960-121.998
TTM213.9625Y77.074+136.888
5Y77.07410Y77.0740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ325.525-0.032+325.557
TTM213.9620.004+213.958
YOY335.9600.016+335.944
5Y77.0740.006+77.068
10Y77.0740.003+77.071

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Evelo Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.39 means the investor is paying $6.39 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Evelo Biosciences Inc:

  • The EOD is 6.544. Seems overpriced? -1
  • The MRQ is 6.392. Seems overpriced? -1
  • The TTM is 20.806. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD6.544MRQ6.392+0.151
MRQ6.392TTM20.806-14.414
TTM20.806YOY22.792-1.986
TTM20.8065Y12.573+8.232
5Y12.57310Y10.933+1.640
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.5441.835+4.709
MRQ6.3922.006+4.386
TTM20.8062.774+18.032
YOY22.7923.453+19.339
5Y12.5732.713+9.860
10Y10.9332.402+8.531
2. Total Gains per Share

2.4. Latest News of Evelo Biosciences Inc

Does Evelo Biosciences Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Evelo Biosciences Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-12-01
13:40
Evelo Biosciences, Inc. (NASDAQ:EVLO) insiders placed bullish bets worth US$575k in the last 12 monthsRead
2022-11-15
22:01
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in ImmunologyRead

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Evelo Biosciences Inc.

3.1. Institutions holding Evelo Biosciences Inc

Institutions are holding 82.704% of the shares of Evelo Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-06-30Flagship Ventures Management, Inc.46.69474.00815042732827397259118.963
2022-06-30FMR Inc14.98760.0034161857098139220101.1524
2022-09-30State Treasurer State Of Michigan3.76940.0625407072800
2022-06-30Credit Suisse First Boston (CSFB)3.40270.00813674726-2438-0.0663
2022-06-30Harbourvest Partners, LLC2.83672.1212306350500
2022-06-30CVI Holdings LLC1.90270.3153205479420547940
2022-06-30Vanguard Group Inc1.25960.00011360322-184196-11.9258
2022-06-30Geode Capital Management, LLC0.32110.0001346726-199197-36.4881
2022-06-30abrdn PLC0.31710.00233424653424650
2022-06-30Ergoteles LLC0.28180.01923043293043290
2022-06-30EcoR1 Capital, LLC0.18560.01462004172004170
2022-06-30Millennium Management LLC0.17880.0003193134149605343.6904
2022-06-30Charles Schwab Investment Management Inc0.11040.0001119267-85736-41.8218
2022-06-30Citadel Advisors Llc0.09950.00011074234438670.4126
2022-06-30State Street Corporation0.0872094158-484703-83.7339
2022-06-30Northern Trust Corp0.0668072135-214836-74.8633
2022-06-30Bessemer Group Inc0.05680.00036128900
2022-06-30AE Wealth Management LLC0.05190.0009560292459278.2263
2022-06-30Goldman Sachs Group Inc0.0389042039-11920-22.0908
2022-06-30Qube Research & Technologies0.02850.000530760307600
Total 76.67786.557182807283+37504801+45.3%

3.2. Funds holding Evelo Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-09-30Fidelity Growth Compy Commingled Pl 35.70360.02776159480104430.1698
2022-09-30Fidelity® Growth Company4.60720.0266497553900
2022-09-30DNCA Invest Beyond Global Leaders I EUR3.62591.66743915737-2322-0.0593
2022-09-30CS (Lux) Digital Health Equity SB USD3.33350.3287360000000
2022-09-30Vanguard Instl Ttl Stck Mkt Idx Tr1.93620.000420909671163105125.3532
2022-10-31Vanguard Total Stock Mkt Idx Inv1.93620.0004209096700
2022-09-30Fidelity® Growth Company K61.21570.02821312873-10443-0.7892
2022-09-30Fidelity® Series Growth Company1.18190.02451276364133501.057
2022-09-30Fidelity® Select Biotechnology1.01770.0452109899900
2022-10-31Vanguard Extended Market Index Investor0.94670.00251022375-21946-2.1015
2022-09-30Fidelity® VIP Growth Initial0.43230.01546690000
2022-10-31iShares Biotechnology ETF0.38960.010642069520100.4801
2022-09-30Fidelity® Capital Appreciation0.35130.01637940000
2022-09-30Fidelity® Extended Market Index0.26250.002128345112643680.5248
2022-10-31BSO Bio Santé C0.25930.271728000000
2022-09-30Fidelity Advisor® Equity Growth I0.24830.013926820000
2022-09-30Fidelity® Growth Discovery0.17370.015318760000
2022-09-30Fidelity® Total Market Index0.09430.000410184958374134.2703
2022-10-31Club Innovation Santé0.07410.30528000000
2022-09-30Fidelity® Series Total Market Index0.07240.00047822548304161.4385
Total 27.86242.802230089621+1387311+4.6%

3.3. Insider Transactions

Insiders are holding 0.13% of the shares of Evelo Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630
2022-05-27Ventures Fund Iv Gene FlagshipBUY273972591.4613698630

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Evelo Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.486-0.061+113%-0.016+103%0.014+3383%0.014+3284%
Book Value Growth--1.471-0.935+164%-0.197+113%-0.192+113%-0.174+112%
Book Value Per Share--0.3300.140+135%0.534-38%0.624-47%0.550-40%
Book Value Per Share Growth--1.471-0.935+164%-0.197+113%-0.192+113%-0.174+112%
Current Ratio--4.5254.002+13%5.843-23%9.349-52%8.434-46%
Debt To Asset Ratio--0.6810.896-24%0.545+25%0.464+47%0.495+38%
Debt To Equity Ratio--2.1393.450-38%1.283+67%1.278+67%1.317+62%
Dividend Per Share----0%-0%-0%-0%
Eps---0.283-0.284+0%-0.254-10%-0.214-24%-0.190-33%
Eps Growth---0.0230.013-281%-0.093+304%-0.042+84%-0.042+84%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio6.544+2%6.39220.806-69%22.792-72%12.573-49%10.933-42%
Pe Ratio-7.633-2%-7.456-16.284+118%-40.022+437%-32.878+341%-28.590+283%
Peg Ratio--325.525213.962+52%335.960-3%77.074+322%77.074+322%
Price Per Share2.160+2%2.1104.653-55%10.450-80%6.660-68%5.791-64%
Price To Total Gains Ratio4.447+2%4.344-15.772+463%-33.315+867%-30.974+813%-30.974+813%
Profit Growth---2.2911.266-281%-9.252+304%-6.674+191%-0.036-98%
Quick Ratio--4.2913.828+12%5.695-25%9.994-57%8.690-51%
Return On Assets---0.273-0.349+28%-0.231-16%-0.225-17%-0.255-7%
Return On Equity---0.857-1.296+51%-0.549-36%-0.573-33%-0.653-24%
Total Gains Per Share--0.486-0.061+113%-0.016+103%0.014+3383%0.014+3284%
Total Gains Per Share Growth--1.4860.380+291%-1.132+176%-0.293+120%-0.293+120%
Usd Book Value--35648000.00015147250.000+135%57711750.000-38%67431950.000-47%59357260.870-40%
Usd Book Value Change Per Share--0.486-0.061+113%-0.016+103%0.014+3383%0.014+3284%
Usd Book Value Per Share--0.3300.140+135%0.534-38%0.624-47%0.550-40%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.283-0.284+0%-0.254-10%-0.214-24%-0.190-33%
Usd Price Per Share2.160+2%2.1104.653-55%10.450-80%6.660-68%5.791-64%
Usd Profit---30561000.000-30701000.000+0%-27441750.000-10%-21749900.000-29%-20002652.174-35%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.486-0.061+113%-0.016+103%0.014+3383%0.014+3284%
 EOD+3 -2MRQTTM+22 -5YOY+13 -145Y+12 -1510Y+11 -16

4.2. Fundamental Score

Let's check the fundamental score of Evelo Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.633
Price to Book Ratio (EOD)Between0-16.544
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.291
Current Ratio (MRQ)Greater than14.525
Debt to Asset Ratio (MRQ)Less than10.681
Debt to Equity Ratio (MRQ)Less than12.139
Return on Equity (MRQ)Greater than0.15-0.857
Return on Assets (MRQ)Greater than0.05-0.273
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Evelo Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.150
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets111,901
Total Liabilities76,253
Total Stockholder Equity35,648
 As reported
Total Liabilities 76,253
Total Stockholder Equity+ 35,648
Total Assets = 111,901

Assets

Total Assets111,901
Total Current Assets97,010
Long-term Assets97,010
Total Current Assets
Cash And Cash Equivalents 92,007
Other Current Assets 5,003
Total Current Assets  (as reported)97,010
Total Current Assets  (calculated)97,010
+/-0
Long-term Assets
Property Plant Equipment 13,736
Other Assets 1,155
Long-term Assets  (as reported)14,891
Long-term Assets  (calculated)14,891
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities21,441
Long-term Liabilities54,812
Total Stockholder Equity35,648
Total Current Liabilities
Short-term Debt 8,033
Short Long Term Debt 5,928
Accounts payable 2,248
Other Current Liabilities 3,660
Total Current Liabilities  (as reported)21,441
Total Current Liabilities  (calculated)19,869
+/- 1,572
Long-term Liabilities
Long term Debt Total 40,746
Capital Lease Obligations 8,671
Long-term Liabilities Other 6,566
Long-term Liabilities  (as reported)54,812
Long-term Liabilities  (calculated)55,983
+/- 1,171
Total Stockholder Equity
Common Stock108
Retained Earnings -475,117
Capital Surplus 510,657
Total Stockholder Equity (as reported)35,648
Total Stockholder Equity (calculated)35,648
+/-0
Other
Capital Stock108
Cash and Short Term Investments 92,007
Common Stock Shares Outstanding 75,719
Common Stock Total Equity108
Current Deferred Revenue7,500
Liabilities and Stockholders Equity 111,901
Net Debt -36,662
Net Invested Capital 82,322
Net Tangible Assets 35,648
Net Working Capital 75,569
Short Long Term Debt Total 55,345



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
18,570
0
0
0
43,788
122,313
188,288
175,606
159,867
141,934
126,208
111,140
90,920
83,147
113,905
104,837
90,639
153,042
145,058
116,458
87,871
58,825
111,901
111,90158,82587,871116,458145,058153,04290,639104,837113,90583,14790,920111,140126,208141,934159,867175,606188,288122,31343,78800018,570
   > Total Current Assets 
15,720
0
0
0
38,777
115,187
180,876
168,039
151,622
133,282
117,298
101,231
81,009
60,993
92,717
84,559
70,980
134,181
126,367
97,915
71,026
43,125
97,010
97,01043,12571,02697,915126,367134,18170,98084,55992,71760,99381,009101,231117,298133,282151,622168,039180,876115,18738,77700015,720
       Cash And Cash Equivalents 
15,536
0
0
0
38,246
114,311
178,902
79,713
93,101
105,490
109,475
97,061
77,833
58,115
90,173
81,580
68,857
124,591
123,333
95,938
68,441
39,631
92,007
92,00739,63168,44195,938123,333124,59168,85781,58090,17358,11577,83397,061109,475105,49093,10179,713178,902114,31138,24600015,536
       Short-term Investments 
0
0
0
0
0
0
0
84,615
54,818
23,949
3,998
0
0
0
0
0
0
0
0
0
0
0
0
0000000000003,99823,94954,81884,6150000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,500
0
0
0
0
0
000007,50000000000000000000
       Other Current Assets 
184
0
0
0
531
876
1,974
3,711
3,703
3,843
3,825
4,170
3,176
2,878
2,544
2,979
2,123
2,090
3,034
1,977
2,585
3,494
5,003
5,0033,4942,5851,9773,0342,0902,1232,9792,5442,8783,1764,1703,8253,8433,7033,7111,974876531000184
   > Long-term Assets 
0
0
0
0
5,011
7,126
7,412
7,567
8,245
8,652
8,910
9,909
9,911
22,154
21,188
20,278
19,659
18,861
18,691
18,543
16,845
15,700
14,891
14,89115,70016,84518,54318,69118,86119,65920,27821,18822,1549,9119,9098,9108,6528,2457,5677,4127,1265,0110000
       Property Plant Equipment 
2,504
0
0
0
3,496
4,429
5,912
6,069
6,925
7,332
7,488
8,339
8,341
20,584
19,618
18,778
18,235
17,548
17,376
17,151
15,532
14,545
13,736
13,73614,54515,53217,15117,37617,54818,23518,77819,61820,5848,3418,3397,4887,3326,9256,0695,9124,4293,4960002,504
       Long-term Assets Other 
0
0
0
0
1,515
2,697
1,500
1,498
1,320
1,320
1,422
1,570
1,570
1,570
1,570
1,500
1,424
1,313
1,315
1,392
1,313
1,155
1,155
1,1551,1551,3131,3921,3151,3131,4241,5001,5701,5701,5701,5701,4221,3201,3201,4981,5002,6971,5150000
> Total Liabilities 
13,044
0
0
0
14,385
21,060
23,240
24,846
22,918
23,051
26,120
30,594
30,723
43,803
44,699
54,407
60,154
65,203
82,965
83,382
79,204
75,627
76,253
76,25375,62779,20483,38282,96565,20360,15454,40744,69943,80330,72330,59426,12023,05122,91824,84623,24021,06014,38500013,044
   > Total Current Liabilities 
2,248
0
0
0
3,839
4,617
7,517
9,413
9,235
11,216
9,889
9,675
9,743
12,463
13,608
13,548
19,833
18,719
19,796
20,727
17,362
16,172
21,441
21,44116,17217,36220,72719,79618,71919,83313,54813,60812,4639,7439,6759,88911,2169,2359,4137,5174,6173,8390002,248
       Short-term Debt 
9,931
9,931
0
0
9,966
14,719
14,753
0
0
4,375
282
398
0
1,806
1,788
1,607
1,674
2,656
1,812
1,877
1,951
3,871
8,033
8,0333,8711,9511,8771,8122,6561,6741,6071,7881,80603982824,3750014,75314,7199,966009,9319,931
       Short Long Term Debt 
9,931
9,931
0
0
9,966
14,719
14,753
0
0
4,375
282
398
0
0
0
0
0
914
0
0
0
1,844
5,928
5,9281,844000914000003982824,3750014,75314,7199,966009,9319,931
       Accounts payable 
637
0
0
0
1,411
1,367
2,679
2,880
1,519
1,379
2,693
1,358
620
1,210
3,439
2,729
1,442
380
2,319
2,517
1,601
1,760
2,248
2,2481,7601,6012,5172,3193801,4422,7293,4391,2106201,3582,6931,3791,5192,8802,6791,3671,411000637
       Other Current Liabilities 
1,611
0
0
0
2,428
3,250
4,838
6,533
7,716
9,837
7,196
8,317
9,123
9,447
8,381
9,212
16,717
15,683
15,665
16,333
6,310
10,541
3,660
3,66010,5416,31016,33315,66515,68316,7179,2128,3819,4479,1238,3177,1969,8377,7166,5334,8383,2502,4280001,611
   > Long-term Liabilities 
0
0
0
0
10,546
16,443
15,723
15,433
13,683
11,835
16,231
20,919
20,980
31,340
31,091
40,859
40,321
46,484
63,169
62,655
61,842
59,455
54,812
54,81259,45561,84262,65563,16946,48440,32140,85931,09131,34020,98020,91916,23111,83513,68315,43315,72316,44310,5460000
       Long term Debt Total 
0
0
0
0
0
14,719
14,753
14,155
12,305
10,458
14,856
19,549
19,634
19,720
19,806
29,924
30,048
29,258
46,482
46,520
46,557
44,772
40,746
40,74644,77246,55746,52046,48229,25830,04829,92419,80619,72019,63419,54914,85610,45812,30514,15514,75314,71900000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
0
13,257
12,770
12,110
11,663
11,205
10,736
10,249
9,736
9,210
8,671
8,6719,2109,73610,24910,73611,20511,66312,11012,77013,2570000000000000
       Warrants
0
0
0
0
0
165,778
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000165,77800000
       Long-term Liabilities Other 
0
0
0
0
0
701
80
337
307
280
252
224
198
169
303
10,935
10,273
17,226
263
263
7,785
14,683
6,566
6,56614,6837,78526326317,22610,27310,9353031691982242522803073378070100000
       Deferred Long Term Liability 
0
0
0
0
0
1,023
890
941
1,071
1,097
1,123
1,146
1,148
0
0
0
0
0
0
0
7,500
0
0
007,50000000001,1481,1461,1231,0971,0719418901,02300000
> Total Stockholder Equity
5,526
-28,337
0
0
29,403
101,253
165,048
150,760
136,949
118,883
100,088
80,546
60,197
39,344
69,206
50,430
30,485
87,839
62,093
33,076
8,667
-16,802
35,648
35,648-16,8028,66733,07662,09387,83930,48550,43069,20639,34460,19780,546100,088118,883136,949150,760165,048101,25329,40300-28,3375,526
   Common Stock
4
0
0
0
20
4
32
32
32
32
32
32
32
32
46
46
47
53
53
53
54
54
108
108545453535347464632323232323232324200004
   Retained Earnings Total Equity-475,117-444,556-414,695-386,043-352,313-320,715-292,519-263,469-242,546-221,894-198,853-176,254-154,600-133,700-113,381-97,900-82,080-66,93500000
   Accumulated Other Comprehensive Income 
0
0
0
0
-1,429
-2,014
-2,677
-38
-18
-2
1
-3,209
-3,709
-4,114
-4,648
-5,109
0
-6,179
-6,719
0
0
0
0
0000-6,719-6,1790-5,109-4,648-4,114-3,709-3,2091-2-18-38-2,677-2,014-1,4290000
   Capital Surplus 
0
0
0
0
0
2,406
247,096
248,703
250,316
252,533
254,676
256,768
259,018
261,206
311,706
313,853
322,957
408,501
414,353
419,066
423,308
427,700
510,657
510,657427,700423,308419,066414,353408,501322,957313,853311,706261,206259,018256,768254,676252,533250,316248,703247,0962,40600000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
0
0
0
0
87,223
4,420
249,773
248,703
250,316
252,533
254,676
256,768
259,018
265,320
316,354
318,962
322,957
414,680
421,072
419,066
423,308
427,700
510,657
510,657427,700423,308419,066421,072414,680322,957318,962316,354265,320259,018256,768254,676252,533250,316248,703249,7734,42087,2230000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-115,396
Operating Income-115,396-115,396
 
Operating Expense (+$)
Research Development83,643
Selling General Administrative31,753
Selling And Marketing Expenses-
Operating Expense115,396115,396
 
Net Interest Income (+$)
Interest Income-
Interest Expense-3,612
Net Interest Income-3,612-3,612
 
Pretax Income (+$)
Operating Income-115,396
Net Interest Income-3,612
Other Non-Operating Income Expenses-6,352
Income Before Tax (EBT)-121,748-109,044
EBIT - interestExpense = -118,522
-121,748
-118,564
Interest Expense3,612
Earnings Before Interest and Taxes (ebit)-114,910-118,136
Earnings Before Interest and Taxes (ebitda)-112,694
 
After tax Income (+$)
Income Before Tax-121,748
Tax Provision-428
Net Income From Continuing Ops-122,176-122,176
Net Income-122,176
Net Income Applicable To Common Shares-122,176
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses115,396
Total Other Income/Expenses Net-6,3529,964
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
UIM1.XETRA
1 minute ago

I found you a Golden Cross on the daily chart of UIM1.XETRA.

UIM1.XETRA Daily Candlestick Chart
PGN.XETRA
3 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of PGN.XETRA.

PGN.XETRA Daily Candlestick Chart
LHA.XETRA
3 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of LHA.XETRA.

LHA.XETRA Daily Candlestick Chart
SC06.XETRA
7 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SC06.XETRA.

SC06.XETRA Daily Candlestick Chart
BNN.XETRA
8 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BNN.XETRA.

BNN.XETRA Daily Candlestick Chart
NTG.XETRA
14 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of NTG.XETRA.

NTG.XETRA Daily Candlestick Chart
JUN3.XETRA
15 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JUN3.XETRA.

JUN3.XETRA Daily Candlestick Chart
FEV.XETRA
17 minutes ago

I found you a Golden Cross on the daily chart of FEV.XETRA.

FEV.XETRA Daily Candlestick Chart
EUN2.XETRA
21 minutes ago

I found you a Golden Cross on the daily chart of EUN2.XETRA.

EUN2.XETRA Daily Candlestick Chart
DBPD.XETRA
21 minutes ago

I found you a Death Cross on the daily chart of DBPD.XETRA.

DBPD.XETRA Daily Candlestick Chart
V50A.XETRA
22 minutes ago

I found you a Golden Cross on the daily chart of V50A.XETRA.

V50A.XETRA Daily Candlestick Chart
ETDD.XETRA
24 minutes ago

I found you a Golden Cross on the daily chart of ETDD.XETRA.

ETDD.XETRA Daily Candlestick Chart
CEC.XETRA
25 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CEC.XETRA.

CEC.XETRA Daily Candlestick Chart
XMLC.XETRA
26 minutes ago

I found you a Golden Cross on the daily chart of XMLC.XETRA.

XMLC.XETRA Daily Candlestick Chart
E4C.XETRA
27 minutes ago

I found you a Golden Cross on the daily chart of E4C.XETRA.

E4C.XETRA Daily Candlestick Chart
TULV.TO
27 minutes ago

I found you a Golden Cross on the daily chart of TULV.TO.

TULV.TO Daily Candlestick Chart
ZAL.XETRA
27 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of ZAL.XETRA.

ZAL.XETRA Daily Candlestick Chart
LOTA.V
27 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of LOTA.V.

LOTA.V Daily Candlestick Chart
SPTE.LSE
29 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SPTE.LSE.

SPTE.LSE Daily Candlestick Chart
SHP1.LSE
29 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SHP1.LSE.

SHP1.LSE Daily Candlestick Chart
PLTS.LSE
29 minutes ago

I found you a Death Cross on the daily chart of PLTS.LSE.

PLTS.LSE Daily Candlestick Chart
PDD.LSE
29 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PDD.LSE.

PDD.LSE Daily Candlestick Chart
NRJL.LSE
30 minutes ago

I found you a Death Cross on the daily chart of NRJL.LSE.

NRJL.LSE Daily Candlestick Chart
IEEU.LSE
31 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of IEEU.LSE.

IEEU.LSE Daily Candlestick Chart